SHRO Professor to Discuss Russia's COVID-19 Vaccine in Virtual Event with Columbia University Harriman Institute

Sbarro Health Research Organization (SHRO)

Newswise — Enrico Bucci, Ph.D., Adjunct Professor and long-time international collaborator with the Sbarro Health Research Organization (SHRO) at Temple University, will participate in a panel hosted by Columbia University's Harriman Institute on Monday, March 8, 2021, to discuss Russia's "Sputnik V" COVID-19 vaccine.

The panel of experts will discuss recent trials that have demonstrated efficacy for the vaccine, despite an early release in August 2020 which was met with skepticism by the international community.

The details on the event, via the Harriman Institute:

VIRTUAL EVENT. SPUTNIK V AND RUSSIA’S NEW VACCINE POLITICS: DOMESTIC AND FOREIGN POLICY DIMENSIONS

Monday, March 8, 2021

12:00pm ET

Zoom Webinar & Facebook Live

This event will be held virtually as a Zoom webinar and streamed via YouTube Live. There will be no in-person event.

Register here for the Zoom webinar, or tune in on YouTube Live.

Join us for a meeting of the New York-Russia Public Policy Series, co-hosted by the Harriman Institute at Columbia University and the New York University Jordan Center for the Advanced Study of Russia.

Vladimir Putin’s announcement in August 2020 that Russia had become the first country to grant regulatory approval to a COVID-19 vaccine—Sputnik V—generated much fanfare domestically but was initially met with skepticism among expert global scientific communities. Now, with more published results from trials, we see wider acceptance of the claims of the vaccine’s efficacy and a surging global demand for the vaccine from around the world. Please join this distinguished panel of researchers and commentators as we explore how the vaccine was developed in Russia, the issues surrounding its scientific review, and how the Kremlin is now incorporating “vaccine diplomacy” into its broader foreign policy strategy.

This event is supported by a grant from the Carnegie Corporation of New York.

SPEAKERS

Enrico Bucci, Adjunct Professor of Biology; Director of the System Biology program of the Sbarro Health Research Organization, Temple University

Judyth Twigg, Professor of Political Science at Virginia Commonwealth University

Joshua Yaffa, correspondent for The New Yorker based in Moscow

Alexandra Yatsyk, University of Tartu

Moderated by:

Alexander Cooley, Director of the Harriman Institute, Columbia University

Joshua Tucker, Director of the Jordan Center for the Advanced Study of Russia, New York University

Event Video

About the Sbarro Health Research Organization (SHRO)

The Sbarro Health Research Organization is a non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and related chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism (www.shro.org)

 



Filters close

Showing results

110 of 5809
Newswise: 267646_web.jpg
Released: 11-Jun-2021 2:10 PM EDT
Saliva can be more effective than nasopharyngeal swabs for COVID-19 testing
Elsevier

The collection of nasopharyngeal swab (NPS) samples for COVID-19 diagnostic testing poses challenges including exposure risk to healthcare workers and supply chain constraints.

Released: 11-Jun-2021 1:25 PM EDT
Physical Activity May Curb Health Care Worker Burnout
University of Georgia

More physical activity programming could mitigate the effects of stress and improve worker mental and emotional health.

Newswise: AI Predicts How Patients with Viral Infections, Including COVID-19, Will Fare
9-Jun-2021 6:05 PM EDT
AI Predicts How Patients with Viral Infections, Including COVID-19, Will Fare
University of California San Diego Health

UC San Diego School of Medicine researchers discovered gene expression patterns associated with pandemic viral infections, providing a map to help define patients’ immune responses, measure disease severity, predict outcomes and test therapies — for current and future pandemics.

Released: 10-Jun-2021 5:35 PM EDT
Senolíticos reducen síntomas de COVID-19 en estudios preclínicos
Mayo Clinic

Los investigadores de Mayo Clinic y sus colegas de la Universidad de Minnesota demostraron que la COVID-19 exacerba las consecuencias nocivas de las células senescentes en el cuerpo. En estudios preclínicos, los fármacos senolíticos descubiertos en Mayo redujeron considerablemente la inflamación, la enfermedad y la mortalidad debida a la infección por covid en ratones ancianos. Los resultados se publican en la revista Science.

Released: 10-Jun-2021 5:30 PM EDT
Senolíticos reduzem os sintomas de COVID-19 em estudos pré-clínicos
Mayo Clinic

Os pesquisadores da Mayo Clinic e colegas da Universidade de Minnesota mostraram que o COVID-19 intensifica o impacto prejudicial das células senescentes no corpo. Em estudos pré-clínicos, os medicamentos senolíticos descobertos na Mayo reduziram significativamente a inflamação, a gravidade da doença e a mortalidade da infecção por COVID em camundongos mais velhos. Essas conclusões foram publicadas na revista Science.

Newswise: FresnoSTateVaxImage2.jpg
Released: 10-Jun-2021 5:25 PM EDT
CSU Campuses Join COVID-19 College Vaccine Challenge
California State University (CSU) Chancellor's Office

The CSU pledges to be a Vaccine Champion University as part of new White House effort aimed at increasing vaccinations for younger Americans.

Released: 10-Jun-2021 5:05 PM EDT
الأدوية المحللة للشيخوخة تقلل من أعراض فيروس كورونا المستجد (كوفيد-19) في الدراسات ما قبل السريرية
Mayo Clinic

أظهر باحثو مايو كلينك وزملاؤهم في جامعة مينيسوتا أن فيروس كورونا المستجد (كوفيد-19) يفاقم التأثير الضار للخلايا الشائخة في الجسم. ففي الدراسات ما قبل السريرية، قللت الأدوية المحللة لالشيخوخة التي تم اكتشافها في مايو بشكل كبير من الالتهاب والمرض والوفيات الناجمة عن عَدوى فيروس كورونا المستجد في الفئران الأكبر سنًا. النتائج منشورة في مجلة ساينس.

7-Jun-2021 7:05 AM EDT
Study Examines the Effects of COVID-19 on Human Kidney Cells
American Society of Nephrology (ASN)

• The virus that causes COVID-19 can infect and replicate in human kidney cells, but this does not typically lead to cell death. • Kidney cells that already have features of injury may be more easily infected and develop additional injury.

Released: 10-Jun-2021 4:55 PM EDT
抗衰老药物在临床前研究中减少COVID-19症状。
Mayo Clinic

妙佑医疗国际(Mayo Clinic)的研究人员和明尼苏达大学的同事表明,COVID-19(2019冠状病毒病)加剧了体内衰老细胞的破坏性影响。在临床前研究中,妙佑医疗国际研发的抗衰老药物显著降低了老年实验鼠因COVID(冠状病毒病)感染引起的炎症、疾病和死亡率。该研究结果已发表在《科学》期刊中。

Newswise: blobid0_1623274320110.jpg
Released: 10-Jun-2021 4:45 PM EDT
How does COVID-19 affect patients with cancer? Largest U.S. study shares first results
University of Alabama at Birmingham

New findings include a significant increase in risk of death among patients who had recently had chemotherapy.


Showing results

110 of 5809

close
1.52282